Mara Rubino

Mara Rubino

Auto-generated profile, based on publicly available information

Mara Rubino

Centro Cardiologico Monzino, I.R.C.C.S, Milan, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in JACC
Verified
Journal Article
Closed access
DCDaniela Cardinale
Daniela Cardinale
ACAlessandro Colombo
Alessandro Colombo
GLGiuseppina Lamantia
Giuseppina Lamantia
NCNicola Colombo
Nicola Colombo
MCMaurizio Civelli
Maurizio Civelli
CCCarlo M. Cipolla
Carlo M. Cipolla

9 June 2010 in European Heart Journal
Verified
Journal Article
Open access
PDF file
YDYuri D'Alessandra
Yuri D'Alessandra
PDPaolo Devanna
Paolo Devanna
FLFederica Limana
Federica Limana
SSStefania Straino
Stefania Straino
ACAnna Di Carlo
Anna Di Carlo
MCMaurizio C. Capogrossi
Maurizio C. Capogrossi
Circulating microRNAs (miRNAs) may represent a novel class of biomarkers; therefore, we examined whether acute myocardial infarction (MI) modulates miRNAs plasma levels in humans and mice. Healthy donors (n = 17) and patients (n = 33) with acute ST-segment elevation MI (STEMI) were evaluated. In one cohort (n = 25), the first plasma sample was obtained 517 ± 309 min after the onset of MI symptoms and after coronary reperfusion with percutaneous coronary intervention (PCI); miR-1, -133a, -133b, and -499-5p were ∼15- to 140-fold control, whereas miR-122 and -375 were ∼87–90% lower than control; 5 days later, miR-1, -133a, -133b, -499-5p, and -375 were back to baseline, whereas miR-122 remained lower than control through Day 30. In additional patients (n = 8; four treated with thrombolysis and four with PCI), miRNAs and troponin I (TnI) were quantified simultaneously starting 156 ± 72 min after the onset of symptoms and at different times thereafter. Peak miR-1, -133a, and -133b expression and TnI level occurred at a similar time, whereas miR-499-5p exhibited a slower time course. In mice, miRNAs plasma levels and TnI were measured 15 min after coronary ligation and at different times thereafter. The behaviour of miR-1, -133a, -133b, and -499-5p was similar to STEMI patients; further, reciprocal changes in the expression levels of these miRNAs were found in cardiac tissue 3–6 h after coronary ligation. In contrast, miR-122 and -375 exhibited minor changes and no significant modulation. In mice with acute hind-limb ischaemia, there was no increase in the plasma level of the above miRNAs. Acute MI up-regulated miR-1, -133a, -133b, and -499-5p plasma levels, both in humans and mice, whereas miR-122 and -375 were lower than control only in STEMI patients. These miRNAs represent novel biomarkers of cardiac damage.

3 February 2009 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
Giancarlo MarenziGiancarlo Marenzi
Giancarlo Marenzi
EAEmilio Assanelli
Emilio Assanelli
JCJeness Campodonico
Jeness Campodonico
GLGianfranco Lauri
Gianfranco Lauri
IMIvana Marana
Ivana Marana
ABAntonio L. Bartorelli
Antonio L. Bartorelli
Contrast-induced nephropathy (CIN) frequently occurs in patients with acute ST-segment elevation myocardial infarction (STEMI) who are undergoing primary percutaneous coronary intervention, and CIN is associated with a more complicated clinical course and increased mortality. To investigate the association between absolute and weight- and creatinine-adjusted contrast volume, CIN incidence, and clinical outcome in the era of mechanical reperfusion of STEMI. Prospective, observational study. A university cardiology center in Milan, Italy. 561 consecutive patients with STEMI who were undergoing primary percutaneous coronary intervention. For each patient, the maximum contrast dose was calculated, according to the formula (5 × body weight [kg])/serum creatinine, and the contrast ratio, defined as the ratio between the contrast volume administered and the maximum dose calculated, was assessed. An increase in serum creatinine of more than 25% from baseline was defined as CIN. 115 (20.5%) patients developed CIN. In-hospital mortality was higher among patients with CIN than those without CIN (21.4% vs. 0.9%; P < 0.001). The maximum contrast dose was exceeded in 130 (23%) patients. Patients who received more than the maximum contrast dose (contrast ratio >1) had a more complicated in-hospital clinical course and higher mortality rate (13% vs. 2.8%; P < 0.001) than did patients with a contrast ratio less than 1. Development of CIN was associated with both contrast volume and contrast ratio. The association between contrast volume and outcomes was observed in a single center and could be due to comorbid conditions, disease severity, or an unknown factor. During primary percutaneous coronary intervention for STEMI, higher contrast volume is associated with higher rates of CIN and mortality; however, further study is needed to determine whether limiting contrast volume would improve patient outcome. Centro Cardiologico Monzino, Institute of Cardiology, University of Milan.

1 February 2010 in Critical Care Medicine
Verified
Journal Article
Closed access
Giancarlo MarenziGiancarlo Marenzi
Giancarlo Marenzi
EAEmilio Assanelli
Emilio Assanelli
JCJeness Campodonico
Jeness Campodonico
MMMonica De Metrio
Monica De Metrio
GLGianfranco Lauri
Gianfranco Lauri
ABAntonio L. Bartorelli
Antonio L. Bartorelli
To evaluate the clinical and prognostic relevance of acute kidney injury (AKI) in the setting of ST-elevation acute myocardial infarction (STEMI) complicated by cardiogenic shock (CS). Prospective study. Single-center study, 13-bed intensive cardiac care unit at a University Cardiological Center. Ninety-seven consecutive STEMI patients with CS at admission, undergoing intra-aortic balloon pump (IABP) support and primary percutaneous coronary intervention (PCI). None. We measured serum creatinine at baseline and each day for the following 3 days. Acute kidney injury was defined as a rise in creatinine >25% from baseline. Overall, AKI occurred in 52 (55%) patients, and in 12 of these patients, a renal replacement therapy was required. In multivariate analysis, age >75 yrs (p = .005), left ventricular ejection fraction ≤40% (p = .009), and use of mechanical ventilation (p = .01) were independent predictors of AKI. Patients developing AKI had a longer hospital stay, a more complicated clinical course, and significantly higher mortality rate (50% vs. 2.2%; p <.001) than patients without AKI. In our population, AKI was the strongest independent predictor of in-hospital mortality (relative risk 12.3, 95% confidence intervals 1.78 to 84.9; p <.001). In patients with STEMI complicated by CS, AKI represents a frequent clinical complication associated with a poor prognosis.

15 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YDYuri D'Alessandra
Yuri D'Alessandra
MCMaria Cristina Carena
Maria Cristina Carena
LSLiana Spazzafumo
Liana Spazzafumo
FMFederico Martinelli
Federico Martinelli
BBBeatrice Bassetti
Beatrice Bassetti
Giulio PompilioGiulio Pompilio
Giulio Pompilio
We examined circulating miRNA expression profiles in plasma of patients with coronary artery disease (CAD) vs. matched controls, with the aim of identifying novel discriminating biomarkers of Stable (SA) and Unstable (UA) angina. An exploratory analysis of plasmatic expression profile of 367 miRNAs was conducted in a group of SA and UA patients and control donors, using TaqMan microRNA Arrays. Screening confirmation and expression analysis were performed by qRT-PCR: all miRNAs found dysregulated were examined in the plasma of troponin-negative UA (n=19) and SA (n=34) patients and control subjects (n=20), matched for sex, age, and cardiovascular risk factors. In addition, the expression of 14 known CAD-associated miRNAs was also investigated. Out of 178 miRNAs consistently detected in plasma samples, 3 showed positive modulation by CAD when compared to controls: miR-337-5p, miR-433, and miR-485-3p. Further, miR-1, -122, -126, -133a, -133b, and miR-199a were positively modulated in both UA and SA patients, while miR-337-5p and miR-145 showed a positive modulation only in SA or UA patients, respectively. ROC curve analyses showed a good diagnostic potential (AUC ≥ 0.85) for miR-1, -126, and -483-5p in SA and for miR-1, -126, and -133a in UA patients vs. controls, respectively. No discriminating AUC values were observed comparing SA vs. UA patients. Hierarchical cluster analysis showed that the combination of miR-1, -133a, and -126 in UA and of miR-1, -126, and -485-3p in SA correctly classified patients vs. controls with an efficiency ≥ 87%. No combination of miRNAs was able to reliably discriminate patients with UA from patients with SA. This work showed that specific plasmatic miRNA signatures have the potential to accurately discriminate patients with angiographically documented CAD from matched controls. We failed to identify a plasmatic miRNA expression pattern capable to differentiate SA from UA patients.

1 December 2010 in American Heart Journal
Verified
Journal Article
Closed access
Giancarlo MarenziGiancarlo Marenzi
Giancarlo Marenzi
MMMonica De Metrio
Monica De Metrio
MRMara Rubino
Mara Rubino
GLGianfranco Lauri
Gianfranco Lauri
ACAnnalisa Cavallero
Annalisa Cavallero
ABAntonio L. Bartorelli
Antonio L. Bartorelli